| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NCPRHEUM0292 |
| P698 | PubMed publication ID | 16951696 |
| P2093 | author name string | Steffen Gay | |
| Diego Kyburz | |||
| Fabia Brentano | |||
| P2860 | cites work | Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors | Q29615065 |
| Antimalarials for rheumatoid arthritis | Q33908151 | ||
| Toll-like receptors direct antimicrobial immune responses— and driving arthritis? | Q35580525 | ||
| Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides | Q37876840 | ||
| Inhibition of mitogen-activated protein kinase signaling by chloroquine | Q40733870 | ||
| Antimalarial drugs in the treatment of rheumatological diseases | Q41560764 | ||
| Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism | Q41921412 | ||
| Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications | Q41930813 | ||
| Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes. | Q41945241 | ||
| RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. | Q46687345 | ||
| P433 | issue | 9 | |
| P921 | main subject | toll-like receptor | Q408004 |
| hydroxychloroquine | Q421094 | ||
| P304 | page(s) | 458-459 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Nature Clinical Practice Rheumatology | Q15752269 |
| P1476 | title | Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling | |
| P478 | volume | 2 |
| Q28475036 | A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults |
| Q38111423 | A review on guidelines for management and treatment of common variable immunodeficiency |
| Q37982634 | An update on the pathogenesis and treatment of IgA nephropathy |
| Q38034270 | Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity |
| Q37627829 | Chloroquine inhibits human CD4+ T-cell activation by AP-1 signaling modulation. |
| Q36309457 | Chronic use of chloroquine disrupts the urine concentration mechanism by lowering cAMP levels in the inner medulla |
| Q36993221 | Developments in the scientific understanding of lupus |
| Q37859679 | Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease |
| Q39044818 | Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function |
| Q34653277 | HIV-associated chronic immune activation |
| Q33997226 | How I treat common variable immune deficiency |
| Q52676433 | Hydroxychloroquine attenuates renal ischemia/reperfusion injury by inhibiting cathepsin mediated NLRP3 inflammasome activation. |
| Q36906782 | Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients |
| Q36843689 | Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers |
| Q64069038 | Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study |
| Q38285841 | Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases |
| Q38029146 | Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects |
| Q37854742 | Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy |
| Q37827403 | Hydroxychloroquine: from malaria to autoimmunity |
| Q37208955 | Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated inflammatory disease |
| Q39608521 | Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome |
| Q55332003 | Mast Cells Are Activated by Streptococcus pneumoniae In Vitro but Dispensable for the Host Defense Against Pneumococcal Central Nervous System Infection In Vivo. |
| Q30655475 | Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort |
| Q33589316 | Meta-analysis of crowdsourced data compendia suggests pan-disease transcriptional signatures of autoimmunity. |
| Q37805517 | Modulation of toll-like receptor function has therapeutic potential in autoimmune disease |
| Q89285609 | Neuropsychiatric clinical manifestations in elderly patients treated with hydroxychloroquine: a review article |
| Q38816742 | New Perspectives in Rheumatology: Avoiding Antimalarial Toxicity |
| Q34007922 | New concepts in antimalarial use and mode of action in dermatology |
| Q53214093 | New insights into the pathogenesis of IgA nephropathy. |
| Q36477414 | Overexpression of TLR2 and TLR9 on monocyte subsets of active rheumatoid arthritis patients contributes to enhance responsiveness to TLR agonists |
| Q34340333 | Pathogenic and Epiphenomenal Anti-DNA Antibodies in SLE. |
| Q38156069 | Pragmatic approaches to therapy for systemic lupus erythematosus |
| Q37150726 | Primer: Toll-like receptor signaling pathways--what do rheumatologists need to know? |
| Q47760514 | Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus |
| Q37607071 | Regulatory T cells as therapeutic targets in rheumatoid arthritis |
| Q92615849 | Salivary interleukin 6, interleukin 8, interleukin 17A, and tumour necrosis factor α levels in patients with periodontitis and rheumatoid arthritis |
| Q38985926 | Strategies to limit immune-activation in HIV patients. |
| Q33445361 | Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases |
| Q52725381 | The non-haemostatic role of platelets in systemic lupus erythematosus. |
| Q92736091 | The role of microbiome in rheumatoid arthritis treatment |
| Q38561490 | Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases |
| Q36940639 | Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases |
| Q92434466 | Update on novel pharmacological therapies for osteoarthritis |
| Q37803363 | Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients |
Search more.